The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab
https://doi.org/10.14412/2074-2711-2020-1-68-71
Abstract
The paper describes a clinical case in which an 84-year-old patient with non-valvular atrial fibrillation (AF) who took dabigatran 110 mg twice a day developed recurrent ischemic stroke (IS) that caused dysarthria, left-sided hemiparesis, pain sensitivity and movement coordination impairments. At 170 minutes after IS development, idarucizumab was prescribed and thrombolytic therapy (TLT) was performed to neutralize the anticoagulant effect of dabigatran. At 24 hours after TLT, the National Institutes of Health Stroke Scale (NIHSS) scores were observed to decrease from 11 to 8; and repeated brain computed tomography revealed an ischemic focus in the left cerebellar hemisphere with hemorrhagic transformation to hemorrhagic heart attack type I. On day 19 of IS following the reversal of hemorrhagic transformation, dabigatran was resumed at a dose 110 mg twice a day.
The described case, as well as other authors' data that reflect real clinical practice, confirms that the administration of idarucizumab is safe and allows TLT to be performed in patients with AF who develop IS while taking dabigatran.
About the Authors
E. V. Pudov
City Clinical Hospital Five, Nizhny Novgorodsky District
Russian Federation
Russian Federation
34, Nesterov St., Nizhny Novgorod 603005
N. N. Sukhacheva
City Clinical Hospital Five, Nizhny Novgorodsky District
Russian Federation
Russian Federation
34, Nesterov St., Nizhny Novgorod 603005
I. S. Petelina
City Clinical Hospital Five, Nizhny Novgorodsky District
Russian Federation
Russian Federation
34, Nesterov St., Nizhny Novgorod 603005
References
1. Garber JL, Willenborg KL, Rose AE. Analysis of anticoagulant prescribing in nonvalvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection. J Thromb Thrombolysis. 2015 Aug;40(2):248-54. doi: 10.1007/s11239-015-1223-5.
2. Kumar S, Danik SB, Altman RK, et al. Nonvitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiol Rev. 2016 Sep-Oct;24(5):218-23. doi: 10.1097/CRD.0000000000000088.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin inpatients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12): 1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
4. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
5. Ansell JE. Reversing the effect of oral anticoagulant drugs: established and newer options. Am J Cardiovasc Drugs. 2016 Jun;16(3):163-70. doi: 10.1007/s40256-016-0162-7.
6. Revishvili ASh, Shlyakhto EV, Zamyatin MN, et al. Features of emergency medical care for patients receiving direct oral anticoagulants. Conciliation document of the interdisciplinary group of experts. Vestnik aritmologii. 2018;(92): 59-72. (In Russ.).
7. Diener HC, Bernstein R, Butcher K, et al. Thrombolysis and thrombectomyin patients treated with dabigatranwith acute ischemic stroke: expert opinion. Int J Stroke. 2017 Jan; 12(1):9-12. doi: 10.1177/1747493016669849. Epub 2016 Sep 30.
8. Pollack Jr. CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal-full cohort analysis. N Engl J Med. 2017 Aug 3;377(5): 431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11.
9. Pikija S, Sztriha LK, Sebastian Mutzenbach J, et al. Idarucizumab in dabigatran- treated patients with acute ischemic stroke receiving Alteplase: a systematic review of the available evidence. CNS Drugs. 2017 Sep;31(9): 747-757. doi: 10.1007/s40263-017-0460-x.
10. Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumabin cases of ischemictroke or intracranial hemorrhage in Germany – a national case collection. Int J Stroke. 2017 Jun;12(4):383-391. doi: 10.1177/1747493017701944. Epub 2017 Mar 24.
11. Sanak D, Jakubicek S, Cernik D, et al. Intravenous thrombolysis in patientswith acuteischemic stroke after areversal of dabigatran anticoagulation with idarucizumab. J Neurol Neurosurg Psychiatry. 2018 May;89(5): 549-550. doi: 10.1136/jnnp-2017-316449. Epub 2017 Oct 6.
12. Fang CW, Tsai YT, Chou PC, et al. Intravenous thrombolysis in acute ischemic strokeafteridarucizumabreversal of dabigatraneffect: Analysis of the cases from Taiwan. J Stroke Cerebrovasc Dis. 2019 Mar;28(3): 815-820. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.029. Epub 2018 Dec 17.
13. Reperfuzionnaya terapiya ishemicheskogo insul'ta. Klinicheskii protokol [Reperfusion therapy for ischemic stroke. Clinical protocol]. Moscow; 2019. 80 p.] https://medknigaservis.ru/wp-content/uploads/2019/06/NF0014418.pdf
Review
For citations:
Pudov E.V., Sukhacheva N.N., Petelina I.S. The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(1):68-71. (In Russ.) https://doi.org/10.14412/2074-2711-2020-1-68-71
Views: 332
Email this article 